Is mammary not otherwise specified-type sarcoma with CD10 expression a distinct entity? A rare case report with immunohistochemical and ultrastructural study

Diagnostic Pathology

Hua-Ye Ding²  Hua Jin¹  Jing Li²  Guang-Zhi Yang² 

[1] Department of Pathology, The 263rd Hospital of PLA, Beijing, 101149, China;Department of Pathology, The General Hospital of Beijing Military Command, Beijing, 100700, China

关键词: Metaplastic carcinoma;    Phyllodes tumour;    Undifferentiated sarcoma;    CD10;    Breast;    Sarcoma;   

Others  :  807619
DOI  :  10.1186/1746-1596-8-14

 received in 2012-12-20, accepted in 2013-01-23,  发布年份 2013

【 摘 要 】

Mammary sarcoma is extremely rare and the diagnosis is established only after metaplastic carcinomas and malignant phyllodes tumours are excluded. A rare case of not otherwise specified-type sarcoma with CD10 expression in the left breast in a 45-year-old female was presented. It was a high-grade tumour composed of spindle cells histologically. The immunohistochemical results showed that CD10, vimentin and EGFR were positive diffusely and SMA presented focally, whereas epithelial markers and other myoepithelial or myogenic markers were all negative. The electron microscope investigation demonstrated fibroblast-like features. The exact entity of the tumour remains to be studied because it resembles undifferentiated sarcoma or sarcomatoid metaplastic carcinoma to some degree, as well as high-grade malignant phyllodes tumour in particular.

【 授权许可】

   
2013 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Rosen PP: Sarcoma. In Rosen’s Breast Pathology. 3rd edition. Edited by Rosen PP. Philadelphia: Lippincott Williams & Wilkins; 2009:902-959.
• [2]Leibl S, Moinfar F: Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation. Am J Surg Pathol 2006, 30:450-456.
• [3]Mouna B, Saber B, Tijani el H, Hind M, Amina T, Hassan E: Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review. World J Surg Oncol 2012, 10:151. BioMed Central Full Text
• [4]Vela-Chávez TA, Arrecillas-Zamora MD, Quintero-Cuadra LY, Fend F: Granulocytic sarcoma of the breast without development of bone marrow involvement: a case report. Diagn Pathol 2009, 4:2. BioMed Central Full Text
• [5]Moore T, Lee AH: Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast. Histopathology 2001, 38:62-67.
• [6]Silverman JS, Tamsen A: Mammary fibroadenoma and some phyllodes tumour stroma are composed of CD34+ fibroblasts and factor XIIIa + dendrophages. Histopathology 1996, 29:411-419.
• [7]Moritani S, Kushima R, Sugihara H, Bamba M, Kobayashi TK, Hattori T: Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002, 15:397-405.
• [8]Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, Karim RZ, Lee CS: Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005, 58:185-189.
• [9]Tsai WC, Jin JS, Yu JC, Sheu LF: CD10, actin, and vimentin expression in breast phyllodes tumors correlates with tumor grades of the WHO grading system. Int J Surg Pathol 2006, 14:127-131.
• [10]Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K: Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002, 440:589-593.
• [11]Ogawa H, Iwaya K, Izumi M, Kuroda M, Serizawa H, Koyanagi Y, Mukai K: Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002, 33:806-811.
• [12]Lingamfelter D, Chen Y, Kure K, Lankachandra K: Infiltrating myoepithelial carcinoma of the breast, a case report and cytologic-histologic correlation. Diagn Pathol 2008, 3:7. BioMed Central Full Text
• [13]Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
• [14]Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC: Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006, 49:10-21.
• [15]Weigelt B, Kreike B, Reis-Filho JS: Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009, 117:273-280.
• [16]Leibl S, Moinfar F: Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005, 58:700-704.
• [17]Bachelard-Cascales E, Chapellier M, Delay E, Pochon G, Voeltzel T, Puisieux A, de Caron Fromentel C, Maguer-Satta V: The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells 2010, 28:1081-1088.
• [18]Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C: Defining the cellular precursors to human breast cancer. Proc Natl Acad Sci U S A 2012, 109:2772-2777.
• [19]Francoual M, Etienne-Grimaldi MC, Formento JL, Benchimol D, Bourgeon A, Chazal M, Letoublon C, André T, Gilly N, Delpero JR, Lasser P, Spano JP, Milano G: EGFR in colorectal cancer: more than a simple receptor. Ann Onc 2006, 17:962-967.
• [20]Morita S, Okamoto I, Kobayashi K, Yamazaki K, Asahina H, Inoue A, Hagiwara K, Sunaga N, Yanagitani N, Hida T, Yoshida K, Hirashima T, Yasumoto K, Sugio K, Mitsudomi T, Fukuoka M, Nukiwa T: Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res 2009, 15:4493-4498.
• [21]Cohen EE: Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2659-2665.
• [22]Gumuskaya B, Alper M, Hucumenoglu S, Altundag K, Uner A, Guler G: EGFR expression and gene copy number in triple-negative breast carcinoma. Cancer Genet Cytogenet 2010, 203:222-229.
• [23]Babarović E, Zamolo G, Mustać E, Strčić M: High grade angiosarcoma arising in fibroadenoma. Diagn Pathol 2011, 6:125. BioMed Central Full Text
• [24]Wang XY, Jakowski J, Tawfik OW, Thomas PA, Fan F: Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 2009, 13:147-150.
• [25]Li YF, Yu CP, Wu ST, Dai MS, Lee HS: Malignant mesenchymal tumor with leiomyosarcoma, rhabdomyosarcoma, chondrosarcoma, and osteosarcoma differentiation: case report and literature review. Diagn Pathol 2011, 6:35. BioMed Central Full Text